1419, PL-10, PLD-116, PL 14736), in trials for inflammatory bowel disease (LD1 not achieved), wound and fistulas treatment (1-7, 27, 29, 33-37) (i.e., stimulation of expression of the early growth response 1 (egr-1) gene (38), and other molecular pathways (38-42), effective alone without carrier (1-7) it has a particular effect on endothelium protection along with prominent angiogenesis (1, 43-47) and an effect on NO-system (1-7)
4:e00211
For the treatment of prostate cancer
Double-blind multicenter clinical trial on the efficacy of phosphocreatinine vs L-carnitine and placebo in a group of patients affected by heart disease
The compound exists in a legal gray zone as a research chemical legal to possess, unlawful to sell as a therapeutic product
This property is beneficial for bodybuilders and athletes who want to progress as quickly as possible and create a higher percentage of muscle mass